✦ LIBER ✦

Clinical development of a new pharmaceutical form of leuprorelin acetate for the treatment of advanced prostate cancer: Pharmacokinetics of a 3-month implant

✍ Scribed by Thyroff-Friesinger⁎, U.; Geiges, G.; Engert, Z. Vendel

Book ID: 123392692
Publisher: Elsevier
Year: 2012
Tongue: English
Weight: 68 KB
Volume: 3
Category: Article
ISSN: 1879-4068
DOI: 10.1016/j.jgo.2012.10.104

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical development of a new pharmaceut

Clinical development of a new pharmaceutical form of leuprorelin acetate for the treatment of advanced prostate cancer: Studies of a 3-month implant

✍ Thyroff-Friesinger⁎, U.; Geiges, G.; Engert, Z. Vendel 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 64 KB

Clinical development of a new pharmaceut

Clinical development of a new pharmaceutical form of leuprorelin acetate for the treatment of advanced prostate cancer: Studies of a 1-month implant

✍ Thyroff-Friesinger⁎, U.; Geiges, G.; Engert, Z. Vendel 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 79 KB

A new pharmaceutical form of leuprorelin

A new pharmaceutical form of leuprorelin acetate for the treatment of advanced prostate cancer: Clinical experience from a non-interventional study

✍ Thyroff-Friesinger⁎, U.; Geiges, G.; Engert, Z. Vendel 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 67 KB

PCN89 Cost Effectiveness of Treatment Wi

PCN89 Cost Effectiveness of Treatment With New 6-Month Leuprorelin Acetate Formulation in Patients With Advanced Prostate Cancer

✍ N.L. Tundia; M. Fuldeore; D. Gruca; S. Hass; P. Bacher; A. Bodhani 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

A 12-Month Clinical Study of LA-2585 (45

A 12-Month Clinical Study of LA-2585 (45.0 MG): A New 6-Month Subcutaneous Delivery System for Leuprolide Acetate for the Treatment of Prostate Cancer

✍ Crawford, E. David; Sartor, Oliver; Chu, Franklin; Perez, Ramon; Karlin, Gary; G 📂 Article 📅 2006 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 130 KB

P110 Efficacy and tolerability of 3- and

P110 Efficacy and tolerability of 3- and 6-month depot formulations of leuprorelin acetate for advanced prostate cancer in daily clinical practice: Pooled data from 2 non-interventional studies

✍ Ohlmann, C.H.; Gross-Langenhoff, M.; Tunn, U.W. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 70 KB